Stock NKTR NEKTAR THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nektar Therapeutics

Equities

NKTR

US6402681083

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
1.29 USD -0.77% Intraday chart for Nektar Therapeutics +13.16% +128.32%
Jul. 01 Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Comp Value Index CI
Jul. 01 Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Completeness Index CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NEKTAR THERAPEUTICS Stock Nektar Therapeutics
+128.32% 239M
C
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 809B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 624B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 351B
C+
ABBVIE INC. Stock AbbVie Inc.
+7.92% 289B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 240B
B+
NOVARTIS AG Stock Novartis AG
+13.83% 220B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
A+
AMGEN INC. Stock Amgen Inc.
+7.94% 166B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NKTR Stock
  4. Ratings Nektar Therapeutics